| Betegelu Taye, MD | |
|
1906 Belleview Ave Se, Roanoke, VA 24014-1838 | |
| (540) 981-7000 | |
| (540) 853-0931 |
| Full Name | Betegelu Taye |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 20 Years |
| Location | 1906 Belleview Ave Se, Roanoke, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306257118 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 0101256038 (Virginia) | Secondary |
| 207R00000X | Internal Medicine | 0101256038 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Winchester Medical Center Hha | Winchester, VA | Home health agency |
| Winchester Medical Center | Winchester, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Medicine Physicians Of Virginia Llc | 5698842235 | 116 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Entity Name | Carilion Healthcare Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206370 PECOS PAC ID: 5890607253 Enrollment ID: O20031106000273 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Entity Name | Sentara Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265485270 PECOS PAC ID: 8921903923 Enrollment ID: O20031203000466 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Entity Name | Carilion Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730123472 PECOS PAC ID: 9830096585 Enrollment ID: O20040107000472 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Entity Name | Carilion Rockbridge Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174636021 PECOS PAC ID: 4789658261 Enrollment ID: O20040820000838 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Entity Name | Carilion Giles Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194718304 PECOS PAC ID: 3678670221 Enrollment ID: O20070516000487 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Entity Name | Hospitalist Medicine Physicians Of Virginia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770756991 PECOS PAC ID: 5698842235 Enrollment ID: O20081118000789 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Entity Name | Hospitalist Medicine Physicians Of Fredericksburg, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447577572 PECOS PAC ID: 7719179407 Enrollment ID: O20101013000902 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Betegelu Taye, MD 1906 Belleview Ave Se, Roanoke, VA 24014-1838 Ph: (540) 981-7000 | Betegelu Taye, MD 1906 Belleview Ave Se, Roanoke, VA 24014-1838 Ph: (540) 981-7000 |
News Archive
Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.
"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).
The Obesity Action Coalition, The Obesity Society and the American Society for Metabolic and Bariatric Surgery found encouragement in the outcome of today's advisory committee hearing, favoring approval for the first new obesity treatment in more than 10 years.
Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).
Two GlycoNet Investigators are using technology to better understand how sugars in the human body are connected to Alzheimer's disease.
› Verified 9 days ago
Dr. Jed David Gonzalo, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3 Riverside Cir, Roanoke, VA 24016 Phone: 540-224-5170 | |
Dr. Adel M Salama, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111b S Jefferson St, Roanoke, VA 24016 Phone: 540-342-1007 Fax: 540-345-4643 | |
Dr. Daniel Frank Pauly, , M.D., PH.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 Crystal Spring Ave Sw Ste 203, Roanoke, VA 24014 Phone: 540-982-8204 | |
Joshua Gabriel Gazo, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1906 Belleview Ave Se, Roanoke, VA 24014 Phone: 540-981-7000 | |
Joseph L. Austin, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 127 Mcclanahan St Sw, Suite 300, Roanoke, VA 24014 Phone: 540-982-8204 Fax: 540-224-1059 | |
Ali M Yahya, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2213 Stanley Ave Se, Roanoke, VA 24014 Phone: 571-338-9463 | |
Umar Sofi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2001 Crystal Spring Ave Sw Ste 300, Roanoke, VA 24014 Phone: 540-985-8505 Fax: 540-344-3313 |